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LP-BM5 retrovirus complex-infected C57BL/6 mice develop immunodeficiency, somewhat analogous to
AIDS, termed murine AIDS (MAIDS). After secondary stimulation with syngeneic B-cell lymphomas from
LP-BM5-infected mice, C57BL/6 mice produced vigorous CD8+ cytotoxic T lymphocytes specific for
MAIDS-associated tumors. An anti-LP-BM5 specificity was suggested because spleen and lymph node cells
from LP-BM5-infected mice served as target cells in competition assays, and cells from LP-BM5, but not
ecotropic, virus-infected mice functioned as secondary in vitro stimulators to generate cytotoxic T lymphocytes
to MAIDS tumors.
Recently, several laboratories have described a general-
ized immunodeficiency syndrome in susceptible mouse
strains following infection by a murine retrovirus isolate
termed LP-BM5 (20, 24, 25), that originated from the Du-
plan-Latarjet isolate (19) of murine leukemia virus (MuLV).
The LP-BM5 isolate is a complex mixture of MuLV includ-
ing ecotropic, mink cell focus-inducing, and defective vi-
ruses; currently it is generally agreed that the defective
genome is the proximal agent causing the immunodeficiency
(1, 3, 11, 15). Although this murine immunodeficiency is not
initiated by a lentivirus, the syndrome bears a number of
characteristics similar to those of AIDS and has been termed
murine AIDS (MAIDS). Among the similarities are severe
immunodeficiency of both T- and B-cell responses, depen-
dence of the initiation of disease on the presence of CD4+
T cells, hypergammaglobulinemia, lymphadenopathy, in-
creased susceptibility to progressive infection by environ-
mental pathogens that cause only inapparent infections
without mortality in normal individuals (2, 12, 17, 18, 20,
24-27, 35), and an increased incidence of tumors, parti-
cularly terminal B-cell lineage lymphomas. As has been
suggested for cytotoxic T-lymphocyte (CTL) responses to
human immunodeficiency virus (30, 31, 33, 34), the devel-
opment or, conversely, the lack of the generation of CTLs to
LP-BM5 MuLV-infected cells might play a critical role in the
initiation and maintenance of MAIDS. In the present study
we address the question of whether the prototype MAIDS-
susceptible C57BL/6 (B6) strain can generate CTLs specific
to LP-BM5 MuLV-induced tumors and infected cells.
The B6-1710 and B6-1153 tumors, established as biologi-
cally cloned cell lines from lymphomas from infected B6
mice which had features of MAIDS, are of the B-cell lineage:
B220+, CD5+, Lyb-8+, Ly-17+, ThB+ (17), and Ia+ (Table
1). As to the presence and expression of the virus compo-
nents of the LP-BM5 MuLV complex, assessed via virologic
and molecular probing techniques (references 4 and 16 and
Tables 1 and 2), B6-1710 produced infectious ecotropic
MuLV, but neither tumor produced mink cell focus-inducing
virus. Both tumors carried integrated copies of the defective
* Corresponding author.
genome detectable by Southern blot analysis and, following
cocultivation with cells producing ecotropic MuLV, pro-
duced virus capable of inducing MAIDS. Much higher levels
of mRNA encoded by the defective virus were expressed,
however, by B6-1710 than by B6-1153. Immunoprecipitation
studies of metabolically labeled cells showed that both
MAIDS-associated tumors expressed the Pr60Qag precursor
characteristic of the defective genome (3, 14, 16). As de-
tected by flow cytometry, B6-1710 and B6-1153 readily
expressed both the Db and Kb class I major histocompatibil-
ity complex (MHC) antigens, and as detected by broadly
reactive goat antiserum, they expressed gp7O. Unlike B6-
1710 and control AKR.H-2bSL1 cells, B6-1153 did not
express readily detectable levels of gag-related antigens. A
panel of monoclonal antibodies to distinct env-related deter-
minants, which readily stained the AKR/Gross/Akv+
AKR.H-2bSL1 tumor (8), failed to bind to B6-1153 or
B6-1710, with the exception of those monoclonal antibodies
defining the p15(E)b and p15(E)c epitopes broadly distributed
among MuLV (28, 32).
B6/J or B6/N (B6) mice were immunized with the B6-1710
tumor cell line as a homogeneous source of cells containing
and expressing both the ecotropic and defective viruses in
the LP-BM5 MuLV mixture. Primed spleen cells from
B6-1710-immunized mice were restimulated in vitro with
irradiated homologous tumor cells and tested for cytolytic
activity in standard 4-h 51Cr release assays. This sensitiza-
tion scheme led to the development of vigorously cytolytic
activity to B6-1710 targets (Table 3). This activity appeared
specific in that H-2b+ tumor targets induced by AKR/Gross
MuLV were not lysed at levels significantly above back-
ground (no in vitro restimulation), nor were these AKR/
Gross MuLV-induced tumors able to stimulate B6-1710-
primed cells to exhibit substantial (>10% over background)
lysis of B6-1710 or the other targets. Consistent with a lack
of major antigenic cross-reactivity between this LP-BM5
MuLV-induced tumor and the AKR/Gross MuLV-induced
tumors, anti-AKR/Gross virus CTL induced following im-
munization with (BALB)B.GV, which readily lysed the
H-2b-compatible, susceptible targets EdG2 and AKR.H-
2bSL1 but not cl.18-5 as we have shown previously (8), were
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TABLE 1. Characteristics of MAIDS B-lineage lymphoma lines
AKR.H-2bSLja B6-1710 B6-1153
Cell surface antigensb
and antibodies % Cells TMFI ATMFI % Cells TMFI ATMFI % Cells TMFI ATMFI
positive positive positive
MHC
Expt 1
Anti-DNP 5.0 6 NA 4.8 14 NA 5.6 7 NA
Anti-Dh 99.5 89 83 98.7 107 93 99.7 93 86
Anti-Kb 100.0 381 375 99.7 321 307 100.0 490 483
Expt 2
Anti-ornithine de- - 6.9 29 NA 3.0 12 NA
carboxylase
Anti-I-Ab 99.6 474 445 92.7 380 368C
Viral antigens
Expt 3
Anti-HulgD 16.1 15 NA 1.0 6 NA
Anti-CD8 12.4 14 NA 28.8d 54d NA 0.8 5 NA
Anti-gp70a 95.5 163 149 1.0 8 3
Anti-gp70b 99.0 439 425 25.3d 54 od 1.3 9 4
Anti-gp70c 99.1 154 139 - 1.2 11 5
Anti-gp70d 99.5 421 407 0.3 8 3
Expt 4
Anti-HuCD8 8.1 8 NA 1.2 1 NA
Anti-p15(E)a 55.0 27 19 - 2.4 2 1
Expt 5
Anti-HuFcR,, 17.5 21 NA 11.3 43 NA 3.6 8 NA
Anti-p15(E)b 99.8 125 104 82.3 115 82 4.0 6 0
Anti-p15(E)c 100.0 387 366 96.1 178 135 3.3 7 0
Expt 6
Anti-MAC-2 4.2 2 NA 6.7 7 NA 0.5 1 NA
Anti-gp70V 99.6 116 114 10.8 15 8 0.3 1 0
Anti-gp709 94.8 49 47 11.3 11 4 0.5 1 0
Anti-gp70h 99.2 142 140 11.1 18 11 0.8 1 0
NGS 5.5 20 NA 6.7 32 NA 14.6 8 NA
Anti-AKR gp69-71 99.8 320 300 99.2 337 305 98.5 157 149
Anti-plO 95.8 130 110 94.1 215 183 4.7 6 0
Anti-p12 95.7 130 110 63.8 100 68 7.6 4 0
Anti-p1S 82.1 69 49 56.0 96 64 5.8 6 0
Anti-p30 93.5 129 109 80.5 127 95 12.6 7 0
aTMFI, total mean fluorescence intensity. ATMFI was calculated by subtracting the TMFI from that of the isotype-matched antibody control.-, not
determined; NA, not applicable.
h As determined by flow cytometric analysis. DNP, dinitrophenol; NGS, normal goat serum.
'Initial isolate of B6-1153 was la- (17).
d Staining of B6-1710 was performed with an immunoglobulin G3-specific fluorescein isothiocyanate-conjugated antibody. The data listed for the staining of
AKR.H-2bSL1 and B6-1153 used the fluorescein isothiocyanate-conjugated goat anti-mouse polyvalent antibody, but a similar pattern of reactivity was also
obtained with the immunoglobulin G3-specific secondary antibody.
unable to lyse B6-1710 tumor targets (Table 3). A number of
additional syngeneic tumor targets, including E Y Kl, several
B-cell lineage lines and hybridomas, and those induced by
the Friend-Moloney-Rauscher group of MuLV (MBL2 and
RBL5), and the allogeneic targets P815 (H-2d) and YAC-1
(H-2') were not recognized when employed in direct lytic or
competitive inhibition cytolytic assays (data not shown),
indicating that the lysis of B6-1710 was specific and not due
to natural killer or promiscuous killer activities.
Somewhat surprisingly, a second MAIDS-associated tu-
mor of B6 origin, B6-1153, was a poor target for effector cells
raised against B6-1710, relative to the homologous B6-1710
targets, the level of lysis ranging from low but significant to
questionably positive (Fig. 1A; see also Table 4 below). That
B6-1153 cells were immunogenic and were susceptible to
lysis was shown by generating cytolytic effectors against this
MAIDS-derived tumor by homologous secondary stimula-
tion (Fig. 1D and Table 4). Extensive lysis of B6-1710 targets
by these killer cells was also observed, consistent with the
TABLE 2. Virologic characterization of MAIDS B-lineage
lymphoma lines
Virus content and B6-1710 B6-1153
expression
Infectious MuLVa
Ecotropic 1.8
MCF
Defective MuLVb
DNA + +
mRNA -10x 1x
Pr6099a + +
a The initial isolate of B6-1710 produced infectious mink cell focus-inducing
(MCF) MuLV (4, 17). The value indicates the number of focus-forming units
(loglo) per 107 cells; -, no detectable virus.
h DNA analysis: +, 2 or more integrated copies of defective MuLV genome
detectived by Southern blot hybridization. For mRNA analysis, values indicate
relative levels of expression on Northern blot hybridization. Protein analysis:
+, presence of Pr6Qgaz encoded by the defective virus (3). It was not possible
to compare relative levels expressed in the two lines by immunoprecipitation of
metabolically labeled cells. Primary data on the content and expression of the
defective virus genome in these lines have been presented elsewhere (4, 16).
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TABLE 3. Generation of effector cells cytolytic to the B6-1710
MAIDS-associated tumor: lack of cross-reactivity
with anti-AKR/Gross MuLV CTLsa
% Specific lysis of:
Effector cell stimulator Effector/ AKR.H-2b
target B6 strain: strain:
ratio
In vivo In vitro B6-1710 EcTG2 SL1 cl.18-5
B6-1710 None 20:1 8 4 5 0
B6-1710 20:1 79 4 4 -1
4:1 37 1 1 -1
EdG2 20:1 17 15 8 -1
4:1 5 6 4 -2
AKR.H-2bSLl 20:1 18 6 7 1
4:1 5 4 3 -1
cl.18-5 20:1 16 3 6 -1
(BALB)B.GV None 20:1 2 2 2 -2
EdG2 20:1 0 68 72 -1
4:1 -2 57 54 -2
AKR.H-2bSLl 20:1 -1 64 72 -2
4:1 -2 36 35 -2
cl.18-5 20:1 -2 9 4 -1
B6-1710 20:1 -1 5 2 -1
a C57BL/6 mice were immunized with 106 B6-1710 or (BALB)B.GV tumor
cells 10 days before spleen cells from these mice were removed for secondary
in vitro stimulation. The values of spontaneous release from the target cells
ranged from 8 to 12%, with the exception of B6-1710, whose value was 25%.
recognition of common, presumably LP-BM5 MuLV-asso-
ciated, antigens on the two MAIDS tumors.
To characterize the type of effector cells responsible for
the lysis of the MAIDS tumor lines, responder cells primed
in vivo and restimulated in vitro with the homologous tumor
were treated with various monoclonal antibodies plus com-
plement just prior to the cytolytic assay. In this way the cell
surface phenotype of both of the cytolytic effectors raised
against B6-1710 and against B6-1153 was shown to be
Thy-1+ Ly-2(CD8)+ Ly-4(CD4)-, indicating that the effec-
tors were conventional CD8+ CTLs (data not shown).
The sharing of unique, presumably LP-BM5 MuLV-re-
lated, CTL-defined antigens by B6-1710 and B6-1153 could
be seen more easily by employing the heterologous MAIDS
tumor as a secondary in vitro stimulator cell. In this way it
was clear that B64710 cells expressed an antigen(s) to which
the B6-1153-immunized responder cells had been primed,
resulting in CTLs with nearly comparable activities against
the two targets (Fig. 1C and Table 4). Conversely, B6-1153
tumor stimulator cells also presented a recall antigen(s) to
B6-1710-primed responders (Fig. 1B and Table 4). In this
case, however, the lysis of heterologous B6-1710 targets was
always substantially greater than that of B6-1153 targets.
Collectively, these data suggest that CD8+ CTLs can be
raised to determinants unique to MAIDS-derived tumors and
are most consistent with the existence of at least two
CTL-defined antigen systems: (i) an immunodominant anti-
gen(s) expressed on B6-1710 but either absent or (more
likely) functionally present to a substantially lesser extent on
B6-1153 (Fig. 1A and B) and (ii) an antigen(s) expressed on
both B6-1153 and B6-1710 tumor cells at roughly similar
functional levels (Fig. 1C). This view was strongly supported
by the results with additional target cells (Fig. 1). Panel D is
further consistent with the close relationship of the two
MAIDS-associated tumors but also indicates that secondary
restimulation with B6-1153 additionally results in a lesser
degree of cross-reactive lysis of a number of the other
tumors, particularly E6G2 and RBL5, with even some
recognition of allogeneic targets such as YAC-1 and P815.
Further phenotyping experiments utilizing additional anti-
bodies, including anti-NK1.1, were unsuccessful in allowing
the cells that lysed the non-MAIDS tumors to be character-
ized as a unique effector cell subset.
We next addressed the question of whether cells from B6
mice infected with LP-BM5 MuLV expressed CTL-defined
viral antigens comparable to those defined on the B6-1710
and B6-1153 tumors. Spleen cells from mice 5 to 22 weeks
postinfection were employed as secondary in vitro stimula-
tor cells in an attempt to generate LP-BM5 MuLV-specific
CTL from MAIDS tumor-primed responder cells, based on
our previous observation that the use of normal cells as
secondary in vitro stimulators provided the most sensitive
way to detect AKR/Gross/Akv CTL-defined MuLV deter-
minants in the AKR.H-2b congenic and AKXL recombinant
inbred strains (7, 9). Lymph node (data not shown) and
spleen cells from LP-BM5-infected mice, but not uninfected
mice or those infected with the ecotropic virus component of
the LP-BM5 mixture, stimulated substantial levels of cy-
tolytic activity from both B6-1710- and B6-1153-primed
responder populations (Table 4). Infected spleen cell-restim-
ulated CTL activity was directed only to the MAIDS tumors;
a variety of other tumor cell lines, including Ec&G2, E Y Kl,
AKR.H-2bSL1, cl.18-5, EL4(S), MBL2, RBL5, P815,
YAC-1, and AKR SL8, were not lysed (data not shown). The
specificity of effector cells raised by restimulation with
preparations of LP-BM5 MuLV-infected spleen cells was
further characterized by competitive-inhibition 51Cr release
assays (data not shown). Both effector cells generated after
initial in vivo priming with B6-1710 or B6-1153 tumor cells
recognized spleen and lymph node cells from LP-BM5-
infected mice relative to those from uninfected mice.
The studies presented here provide the first evidence, to
our knowledge, that specific CTL responses can be gener-
ated to LP-BM5 MuLV-derived cells and that these re-
sponses can be elicited by a mouse strain that is susceptible
to MAIDS, B6. The specificity of such CTLs for unique
MuLV-related determinants, rather than tumor-specific an-
tigens, was suggested by the patterns of tumor target lysis
(Tables 1 to 3; Fig. 1), flow cytometric analysis of the
expression of cell surface viral antigens (Table 1), and the
ability to elicit CTL responses specifically effective against
MAIDS tumors following in vitro restimulation with spleen
cells (Table 4) and lymph node cells from LP-BM5 MuLV-
infected B6 mice. These results were thus consistent with
the possibility that if the production of antiviral CTLs occurs
or can be achieved in vivo, the responses may be effective
against infected "normal" cells.
If CTLs are produced in vivo, the destruction of infected
cells by antiviral CTLs might play a role in the MAIDS
disease process in a deleterious way, as has been suggested
for AIDS, by eliminating regulatory Th cells or altering Th
subset distribution and function and thereby contributing to
the development of immunodeficiency (5, 6, 13, 22, 23, 29).
Along these lines, it should be noted that the MHC seems to
control the incidence of MAIDS (10, 21); specifically, the
major determinant of genetic resistance or susceptibility to
MAIDS in crosses between susceptible H-2b and resistant
H-2d mice mapped to H-2D, and rather surprisingly, suscep-
tibility was found to be a dominant trait (21). These results
are thus consistent with the possibility that class I MHC-
restricted recognition of virus-infected cells by CD8+ CTLs
is involved in disease pathogenesis. Alternatively, antiviral
VOL. 66, 1992
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FIG. 1. Summary of target cell specificities of CTLs raised against MAIDS-associated tumors by the direct lytic 5"Cr release assay.
C57BL/6 mice were immunized with 106 B6-1710 (A and B) or 106 B6-1153 (C and D) tumor cells 10 days before spleen cells were removed
for secondary in vitro stimulation with either irradiated B6-1710 (A and C) or B6-1153 (B and D) stimulator cells.
CTL responses might be viewed as helpful in protection
from, or slowing of the progression of, the immunodefi-
ciency if these responses could be enhanced before the
immunodeficiency has become full-blown (see below).
Flow cytometric analyses of viral antigen expression
showed that only B6-1710 expressed gag-related specificities
at readily detectable levels (Table 1). Whether the presences
on B6-1710 of both serologically defined gag-encoded prod-
ucts and a dominant CTL-defined epitope are related is
uncertain. Because of the novel sequences defined for the
p12- and p15-encoding regions of the gag gene of the
defective virus (1, 3, 14) and our finding that LP-BM5-
infected but not LP-BM5-derived ecotropic virus-infected
spleen cells stimulate CTL responses to the MAIDS tumors
(Table 4), it is tempting to speculate, however, that the
antiviral CTLs directed to the dominant CTL epitope pref-
erentially expressed by B6-1710 may be specific for the
defective gag product, which exists as a unique 60-kDa
precursor. The observations that the B6-1153 tumor, al-
though carrying integrated copies of the defective genome,
-J
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TABLE 4. Generation of CTLs directed against B6-1710 and B6-
1153 tumors by stimulation with spleen cells
from LP-BM5-infected micea
Effector cell stimulator Effector/ % Specific
target lysis of:
In vivo In vitro ratio B6-1710 B6-1153
B6-1710 None 100:1 4 -3
B6-1710 100:1 78 13
20:1 57 7
B6-1153 100:1 40 16
20:1 16 8
Normal B6 spleen cells 100:1 4 -2
LP-BM5-infected B6 spleen 100:1 53 19
cells 20:1 31 13
LP-BM5 ecotropic compo- 100:1 2 -1
nent-infected B6 spleen
cells
B6-1153 None 100:1 2 5
B6-1710 100:1 53 45
20:1 36 24
B6-1153 100:1 49 78
20:1 22 51
Normal B6 spleen cells 100:1 0 5
LP-BM5-infected B6 100:1 51 33
Spleen cells 20:1 22 14
LP-BM5 ecotropic compo- 100:1 -1 5
nent-infected B6 spleen
cells
C57BL/6 mice were immunized with 106 B6-1710 or B6-1153 tumor cells
10 days before spleen cells were removed for secondary in vitro stimulation.
Values of spontaneous release from the target cells were 15% for B6-1710 and
16% for B6-1153. B6 spleen cells that were used as stimulator cells were
obtained from either age-matched normal mice or mice that had been infected
with 0.4 ml of either the complete LP-BM5 virus complex or the biologically
cloned ecotropic component of LP-BM5. The titers of infectious ecotropic
virus in the two preparations, as measured by the X-C plaque test, were
approximately equal, being within less than a factor of 2.
appears to express 1/10 as much mRNA related to the
defective virus as does the B6-1710 tumor (Table 1) and
expresses the novel 60-kDagag product in the cytoplasm but
not on the cell surface (16), perhaps indicating aberrant
turnover or processing, are consistent with speculation of a
defective gag-encoded dominant CTL specificity. In addi-
tion, the pattern of lysis of B6-1710 and B6-1153 targets by
CTLs raised via LP-BM5-infected spleen cell restimulation
resembled that following B6-1710 stimulation. The mapping
of resistance to MAIDS to a class I MHC locus, coupled
with the observation that resistance in moderately to highly
resistant strains appeared to develop with age (21), suggests
a role for an immune response of the CTL type. Additional
consistent observations include the finding that tissues from
MAIDS-resistant A/J mice do not contain the defective
genome, as assessed by Southern blot hybridization, at 7 or
12 weeks postinfection whereas the genome is readily de-
tected in tissues of infected B6 mice as soon as 2 weeks
postinfection (4). That the absence of the defective genome
in A/J tissues is mediated through the activity of CD8+ T
cells is strongly suggested by the observations that mice of
this strain treated with anti-CD8 antibodies develop signs of
early MAIDS in association with ready detection of the
defective genome in the spleen by Southern hybridization
(20a). Experiments in which antiviral CTL responses are
developed in resistant strains and employed in adoptive
transfer schemes will be important in establishing a role for
CD8+ CTLs in this clearance of the defective genome.
It should also be pointed out that there is recent evidence
that the B6-1710 tumor presents a gag-related superantigen
to disease-susceptible B6 mice (16). Thus, a strong primary
in vitro proliferative response of spleen cells to irradiated
B6-1710 tumor cells, compared with a very weak response to
B6-1153 stimulator cells, was observed. The response to
B6-1710 displayed all the other hallmarks of a superantigen
response: predominant CD4+ responder cell type, depen-
dence of recognition on class II MHC, and the preferential
expansion of T cells bearing certain V6 T-cell receptor types.
These findings lead to the possibility that an overzealous
response to a retroviral superantigen presented by infected
B-cell lineage antigen-presenting cells is the initiating event
for the immunodeficiency and that CD8+ CTL responses
directed at these antigen-presenting cells could abrogate the
development of the disease.
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